ArticleTranslational lung cancer research2026
Gender disparities in the overall survival of patients with minimally invasive squamous cell carcinoma of the lung: a retrospective analysis of the Surveillance, Epidemiology, and End Results Program database.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In this study, we developed the concept of "minimally invasive lung squamous cell carcinoma" (LUSC), analyzed gender disparities in the overall survival (OS) of patients with this condition, and constructed a survival prediction model for patients with this subtype using data from the Surveillance, Epidemiology, and End Results Program (SEER) database. Methods: The retrospective study analyzed 654 patients diagnosed with minimally invasive LUSC (LUSC meeting the criteria for T1mi in SEER database) between January 2018 and December 2020. Kaplan-Meier survival curves, univariate analysis, and stratified multivariate analysis were applied to evaluate the survival outcomes. A nomogram was created to estimate 14-month survival probabilities, with its effectiveness evaluated via the area under the receiver operating characteristic curve (AUC). Results: The OS rate for patients with minimally invasive LUSC was 65.14% over a maximum follow-up of 35 months. Female patients exhibited significantly better survival outcomes than did males, with a mean survival of 16.28±9.94 and 14.62±10.72 months, respectively (P=0.03). Stratified multivariate analysis revealed that males had a 40% higher risk of mortality than did females [hazard ratio (HR) =1.40, 95% confidence interval (CI): 1.06-1.85; P=0.02]. This disparity was more pronounced in the subgroups, including in male patients aged 60-69 years (HR =2.09; P=0.03) and those with moderately differentiated tumors (HR =2.31; P=0.003), among others. The survival prediction model, which incorporated 13 variables, achieved an AUC of 0.73, indicating good discriminatory performance. Conclusions: This study established concept of minimally invasive LUSC and identified gender as an independent prognostic factor, revealing that male patients have poorer OS. The proposed survival prediction model provides a tool for individualized prognostic assessment and treatment-related decision-making. These findings highlight the need for further refinement of LUSC classification and tailored treatment strategies to improve patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.